RESUMEN
<p><b>OBJECTIVE</b>To explore the clinical effects of T-VD regimen (bortezomib+dexamethasone+thalidomid) and T-VAD regimen (vincristine+adriamycin+dexamethasone+thalidomide) on the patients with multiple myeloma(MM).</p><p><b>METHODS</b>Thirty cases of MM treated by T-VD(T-VD group) and 30 cases of MM treated by T-VAD(T-VAD group) from April 2010 to April 2012 were included in this study. The clinical effects and long-term survival were compared betwwen these 2 groups.</p><p><b>RESULTS</b>Both the CR and ORR in T-VD group were higher than those in T-VAD group(P<0.05); the ORR of the non-light and light chain type in T-VD group was higher than that in the T-VAD group(P<0.05); the ORR was not different between the no-light chain type and light chain type in T-VD group(P>0.05); the ORR was not different between the non-light and light chain type of T-VAD group(P>0.05); the ORR was not different between the stage I-II of T-VD group and T-VAD group(P>0.05); the ORR for the stages of III T-VD group was higher than that of T-VAD group(P<0.05); the ORR was not different between the I-II and III stages in the T-VD group(P>0.05); The ORR for the I-II stages of control group were higher than that of the III stages(P<0.05); the levels of serum M protein, myeloma cells, β2-MG in the T-VD group were lower than those in T-VAD group(P<0.05). The rate of leukocyteopenia, nausea and vomit, weakness in T-VD group were significantly higher than those in T-VAD group(P<0.05); The incidences of infection and peripheral neuropathy in T-VD group were higher than those in T-VAD group(P<0.05).</p><p><b>CONCLUSION</b>The effect of T-VD regimen on the patients with MM is better than that of T-VAD regimen and its effect is not influenced by the clinical classification and stages, but will aggravate some side effects, thus this chemotherapeutic regimen need to be carefully chosen.</p>
RESUMEN
<p><b>OBJECTIVE</b>To explore the effect of CIK cells comined with VAD regimen on prognosis of patients with multiple myeloma(MM).</p><p><b>METHODS</b>Forty-six cases of MM were divided into observation group and control group, the control group was treated by VAD and the observation group was treated by CIK cells comined with VAD. The prognosis between 2 groups was compared.</p><p><b>RESULTS</b>The total efficiency was not significantly different between the 2 groups (P>0.05); the CR in the observation group was significantly higher than that in control group(P<0.05); the levels of osteocytes in observation group were higher than those in control group(P<0.05); the levels of osteoclasts, plasma cells, IgA and IgG in observation group were lower than those in control group(P<0.05); the increasing ranges of albumin and hemoglobin, and the decreasing range of blood sedimentation and β2-MG in observation group were higher than those in control group(P<0.05); the incidences of abnormal electrocardiogram, myocardial enzyme and creatinine in observation group were higher than those in control group(P<0.05).</p><p><b>CONCLUSION</b>CIK cells comined with VAD regimen can enhance the therapeutic effects on the patients with multiple myeloma, improve the objective index and reduce the risk of adverse reactions, thus may be applicable to clinical practice.</p>